Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Davey, e mail them your CV and you should get the job !!
The Company needs to employ a better NOMAD, every RNS begs more questions than it answers. The RNS should have said Tiziana Life Sciences plc (NASDAQ: TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited ("Accustem"), intends to file a listing application with the Nasdaq Stock Market shortly after completion of the LISTING IN LONDON AND ASSOCIATED distribution of shares in Accustem to Tiziana Life Sciences SHAREHOLDERS ON THE RECORD DATE STATED IN RNS XXXX
rather than
Tiziana Life Sciences plc (NASDAQ: TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited ("Accustem"), intends to file a listing application with the Nasdaq Stock Market shortly after completion of the distribution of shares in Accustem to Tiziana Life Sciences plc shareholders.
To someone's point, you do not have to be a current Shareholder in Tiziana to be entitled to, and receive Accustem shares.
The laziness and inaccuracy in some of their RNS's and comms is atrocious, something you can expect on AIM, but they have a main listing so should behave as such.
Excellent news !
They really don't male things easy. My kids could write clearer RNS notes which wouldn't result in even more questions !!
HedgeHogath - thanks for replying. My reading is also that it is Nasdaq only and not LSE. It sounds like a change in thinking from the Board from that original release. Hopefully an interview shortly to clarify.
Pale Ale
to be fair, i'm still reliant on original wording. So maybe, other posters are right maybe it is Nasdaq instead. Initially the intent was UK for sure and maybe US
Here was original wording...
It is intended that Accustem will seek admission to the standard segment of the Official List and admission to trading on the London Stock Exchange plc by way of an IPO in late Q4 2020 ("Accustem Admission") and potentially a dual listing on NASDAQ in 2021.
Sounds like it. Close watch on the account!!
So has this decision been the hold up with issuing Accustem shares , now resolved, so shares issues soon ???
HedgeHogarth - please can you clarify where it's been confirmed that Accustem will be listed in the UK too? It's not in this RNS and the wording that the BoD "has resolved that the Nasdaq listing venue is more appropriate to the nature of Accustem's business" begs the question more appropriate than what alternative (UK? no second listing?). I'd be delighted if you're correct but it would be good to see written confirmation that there will be a UK listing because I can't see it in this RNS. Thanks.
its double listing.....first on LSE and then on Nasdaq!
They know that most of TILS shares are held by UK shareholders!
Hedgehogarth .,.,.,it states "The board of directors of Accustem has resolved that the Nasdaq listing venue is more appropriate to the nature of Accustem's business." Which sounds like it might not be listed on the lse?
Accustem will be listed in the UK too, ithe doubt was whether they would be US listes 'as well'
Todays RNS clears that up.
Does that mean no shares for us in the UK market?
Accustem RNS Out